8VTD

Co-structure of the Fab of the anti-TIGIT Vibostolimab antibody with its antigen

Summary for 8VTD

Entry DOI	10.2210/pdb8vtd/pdb
Descriptor	Vibostolimab Fab Light chain, Vibostolimab Fab Heavy chain, T-cell immunoreceptor with Ig and ITIM domains, ... (5 entities in total)
Functional Keywords	antibody tigit immunotherapy, immune system
Biological source	Mus musculus (house mouse) More
Total number of polymer chains	3
Total formula weight	60675.55
Authors	Fischmann, T. (deposition date: 2024-01-26, release date: 2025-07-02, Last modification date: 2025-09-03)
Primary citation	Fischmann, T.O.,Malashock, D.,Ahn, E.,Wang, H.,Pradhan, K.,Grein, J.,Chakravorty, S.,Bahmanjah, S.,Ban, D.,Chien, E.,Hsieh, M.,Mayhood, T.,Yuan, J.,Wong, J.C.,Beaumont, M.,Baker, J.,McCoy, M.A.,Cai, M.,Wilson, D.,Blumenschein, W.,Williams, S.M.G.,Fayadat-Dilman, L.,Seghezzi, W.,Keenan, T.,Han, J.H. Pharmacological and structural characterization of vibostolimab, a novel anti-TIGIT blocking antibody for cancer immunotherapy. J Immunother Cancer, 13:-, 2025 Cited by PubMed Abstract: Vibostolimab is a humanized anti-T cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT) antibody was recently investigated in late-stage clinical trials. Vibostolimab was developed based on its specific binding property to the human and cynomolgus monkey TIGIT protein and its functional blocking activity of the TIGIT:CD155 interaction. PubMed: 40829901 DOI: 10.1136/jitc-2024-008972 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.23 Å)

Structure validation